Navigation Links
Aida Acquires High-Level Research Institute in China
Date:3/27/2008

Acquisition Expected to Yield Multiple New Drug Products for Aida's

Pipeline

SANTA MONICA, Calif., March 27 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc (OTC Bulletin Board: AIDA) today announced that has acquired one of China's top microbiology research institutes, the Jiangsu Institute of Microbiology Co., Ltd. ("JSIM") Aida's subsidiary, Hanzhou Aida Pharmaceuticals Co., Ltd acquired 43% of the institute from Jinou Medicine Co., Ltd while another of Aida's subsidiaries, Changzhou Fangyuan Pharmaceutical Co., Ltd. acquired an additional 55% from Jiangyin Hi-tech Group. The transaction is expected to close shortly. After the completion of the acquisition, Jiangsu Institute of Microbiology Co., Ltd. will become a subsidiary of Aida Pharmaceuticals. The acquisition is expected to yield multiple new products for Aida, including several that are already in clinical trials by China's State Food and Drug Administration.

Mr. Jin Biao, Chairman and CEO of Aida Pharmaceuticals, noted, "This acquisition will significantly strengthen the research resources of Aida. We are proud to have JSIM in our group and I believe the acquisition will fortify our ability to be an innovative pharmaceutical company in China".

Jiangsu Institute of Microbiology Co., Ltd. ("JSIM") is a national leader in microbiology with over thirty years of research history. JSIM, located in Wuxi City in Jiangsu Province, has over thirty scientists and engineers that have completed over 200 research projects. Over twenty research projects were developed as national-level key projects, as designated by the Chinese government. JSIM's research acumen has been rewarded with numerous patents.

About Aida Pharmaceuticals

Aida Pharmaceuticals is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of advanced pharmaceutical and genetic products in mainland China. The Company's mission is to discover, develop and market meaningful new therapies that improve human health. Aida Pharmaceuticals, in operation since March 1999, is headquartered in Hangzhou, China with manufacturing, distribution and sales points throughout mainland China. Aida is GMP certified in China and ISO9002 certified for quality assurance and ISO14000 certified for ecologically-friendly practices.
For additional information, please visit http://en.aidapharma.com.

Contact Information:

Ashley Hull

(310) 450-9100 opt 1

ashley@leacapital.com

Broker Contact:

Chesapeake Group

(410) 825-3930

Safe Harbor Statement Under The Private Securities Litigation Reform Act of 1995: Except for historical information contained herein, the statements in this news release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company's actual results, performance and achievement in the future to differ materially from forecasted results, performance, and achievement. These risks and uncertainties are described in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.


'/>"/>
SOURCE Aida Pharmaceuticals, Inc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Elsevier Acquires Windhover Information Inc., a Healthcare Business Intelligence Company
2. Nycomed US Inc. Acquires Bradley Pharmaceuticals, Inc.
3. Sirion Therapeutics Acquires Worldwide License to Develop New Treatment for Ocular Diseases
4. Setaram Inc. Acquires Hy-Energy LLC
5. Alexion Acquires All Rights to OMRF Patents Related to Soliris(R)
6. Linc Facility Services Acquires Morse Medical
7. Acrongenomics Acquires Equity Stake in Molecular Vision
8. Inverness Medical Innovations Acquires ParadigmHealth
9. LeMaitre Vascular Acquires Biomateriali, a Vascular Graft Manufacturer
10. Thermo Fisher Scientific Acquires Leading Chromatography Consumables Provider, La-Pha-Pack
11. Raptor Pharmaceuticals Acquires Orphan Clinical Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... ... May 19, 2016 , ... KCAS Bioanalytical and Biomarker Services, ... Director, Large Molecule & Biomarker Bioanalysis. , Dr. Siddiqui has more than 15 ... for preclinical and clinical safety programs. “We’ve seen significant demand for, and we ...
(Date:5/18/2016)... 2016 The Biotech industry continues to ... that there are no opportunities ahead. Today, ActiveWallSt.com has on ... THLD ), Seattle Genetics Inc. (NASDAQ: SGEN ... Corp. (NASDAQ: OPHT ). Sign up now to ... http://www.activewallst.com/ Threshold Pharmaceuticals Inc.,s shares gained ...
(Date:5/17/2016)... -- Haselmeier announces the launch by Merck ... EMA, the European Medicines Agency. Originally launched in 2011 ... new pen version includes enhancements to further improve the ... patients during use. Its enhanced design has ... with a larger display window that improves the readability ...
(Date:5/17/2016)... BASEL, Switzerland , May 17, 2016 /PRNewswire/ ... sciences company located in Basel, Switzerland ... an investigational oral inhibitor of P38 mitogen-activated protein ... ) , Strekin will build the ... Pamapimod in indications in which MAP Kinases play ...
Breaking Biology Technology:
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
Breaking Biology News(10 mins):